DexCom (NASDAQ:DXCM) Price Target Raised to $91.00

DexCom (NASDAQ:DXCM) had its price target hoisted by Citigroup from $85.00 to $91.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the medical device company’s stock.

DXCM has been the subject of a number of other reports. Stifel Nicolaus raised their price objective on shares of DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, August 23rd. Oppenheimer cut their price target on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Canaccord Genuity Group upped their price objective on DexCom from $89.00 to $99.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Royal Bank of Canada dropped their price objective on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Finally, JPMorgan Chase & Co. upped their target price on shares of DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a report on Friday, October 25th. Seven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and a consensus target price of $98.00.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $77.19 on Wednesday. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The company’s 50-day moving average price is $73.58 and its 200 day moving average price is $84.99. DexCom has a 52 week low of $62.34 and a 52 week high of $142.00. The stock has a market cap of $30.15 billion, a price-to-earnings ratio of 46.22, a PEG ratio of 2.46 and a beta of 1.12.

Insider Activity

In other news, EVP Sadie Stern sold 4,259 shares of the firm’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the transaction, the executive vice president now directly owns 71,192 shares in the company, valued at $5,320,178.16. This trade represents a 5.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.30% of the company’s stock.

Institutional Trading of DexCom

Institutional investors and hedge funds have recently bought and sold shares of the business. Migdal Insurance & Financial Holdings Ltd. acquired a new position in DexCom during the second quarter valued at approximately $25,000. Sachetta LLC raised its stake in shares of DexCom by 255.2% in the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after acquiring an additional 171 shares during the period. Riverview Trust Co lifted its holdings in shares of DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after acquiring an additional 232 shares in the last quarter. DT Investment Partners LLC boosted its position in DexCom by 492.2% during the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock worth $43,000 after purchasing an additional 315 shares during the period. Finally, RPg Family Wealth Advisory LLC acquired a new stake in DexCom in the 3rd quarter valued at $57,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.